title: PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses.
abstract: Immune checkpoint inhibitors are designed to restore a patient's own antitumor immune response that has been suppressed during tumor development. The first monoclonal antibodies against the immune checkpoint programmed death 1 (PD-1) receptor, nivolumab and pembrolizumab, are now approved for clinical use. Both agents are indicated for the treatment of advanced melanoma, as well as for the treatment of metastatic non-small cell lung cancer (NSCLC). Nivolumab is also approved for the treatment of advanced renal cell carcinoma. In patients with melanoma, these agents result in objective response rates of ~25-40%, with durable responses lasting more than 2 years in some cases. Results from phase III trials have shown improved survival with nivolumab versus standard-of-care chemotherapy in both patients with advanced melanoma and those with advanced NSCLC. In patients with advanced melanoma, both PD-1 inhibitors (nivolumab and pembrolizumab) have shown improved survival versus ipilimumab. PD-1 inhibitors are associated with adverse events that have immune etiologies, with grade greater than 3 adverse events typically reported in 16% or less of patients. However, most immune-mediated adverse events (including grade 3-4 adverse events) can be managed by using published management algorithms without permanent discontinuation of the agent. As nivolumab and pembrolizumab enter the clinic, and with more PD-1 pathway agents in development for a range of tumor types, this review aims to provide pharmacists with a basic understanding of the role of PD-1 in modulating the immune system and their use in the cancer treatment. The most recent clinical efficacy and safety data are discussed, highlighting the response characteristics distinctive to immune checkpoint inhibitors, along with pharmacokinetic and pharmacodynamic data and cost considerations.
authors.affiliation: Department of Pharmacy: Clinical and Administrative Sciences, The University of Oklahoma College of Pharmacy, Oklahoma City, Oklahoma.
authors.forename: Patrick J
authors.initials: PJ
authors.lastname: Medina
authors.affiliation: Pharmacy Practice and Science Department, University of Kentucky College of Pharmacy, Lexington, Kentucky.
authors.forename: Val R
authors.initials: VR
authors.lastname: Adams
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D059447:Cell Cycle Checkpoints / Q000187:drug effects / Q000276:immunology; D006801:Humans; D056747:Immunomodulation / Q000187:drug effects*; D009369:Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D000077594:Nivolumab; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D061026:Programmed Cell Death 1 Receptor; D000077594:Nivolumab; C582435:pembrolizumab
keywords: PD-1; adverse event; cancer; immune checkpoint blockade; immuno-oncology; oncology; programmed death-1 pathway
references.citation: Proc Natl Acad Sci U S A. 2005 Jul 5;102(27):9571-6
references.pmid: 15980149
references.citation: Immunity. 2000 Aug;13(2):265-76
references.pmid: 10981969
references.citation: Lancet Oncol. 2015 Apr;16(4):375-84
references.pmid: 25795410
references.citation: N Engl J Med. 2015 Jan 22;372(4):320-30
references.pmid: 25399552
references.citation: J Clin Oncol. 2014 Apr 1;32(10):1020-30
references.pmid: 24590637
references.citation: J Clin Oncol. 2015 Jun 20;33(18):2004-12
references.pmid: 25897158
references.citation: N Engl J Med. 2015 May 21;372(21):2018-28
references.pmid: 25891174
references.citation: Clin Cancer Res. 2009 Dec 1;15(23):7412-20
references.pmid: 19934295
references.citation: Clin Cancer Res. 2008 May 15;14(10):3044-51
references.pmid: 18483370
references.citation: N Engl J Med. 2015 Jul 2;373(1):23-34
references.pmid: 26027431
references.citation: Nat Rev Cancer. 2012 Mar 22;12(4):252-64
references.pmid: 22437870
references.citation: Curr Opin Pharmacol. 2015 Aug;23:32-8
references.pmid: 26047524
references.citation: Lancet Oncol. 2015 Mar;16(3):257-65
references.pmid: 25704439
references.citation: N Engl J Med. 2015 Nov 5;373(19):1803-13
references.pmid: 26406148
references.citation: J Clin Oncol. 2015 Aug 10;33(23):2563-77
references.pmid: 26101248
references.citation: J Med Econ. 2013;16(2):202-12
references.pmid: 23057750
references.citation: Clin Dev Immunol. 2012;2012:656340
references.pmid: 22611421
references.citation: Science. 2015 Apr 3;348(6230):124-8
references.pmid: 25765070
references.citation: J Immunol. 2010 Nov 1;185(9):5082-92
references.pmid: 20926790
references.citation: Front Pharmacol. 2012 Feb 10;3:8
references.pmid: 22363283
references.citation: Lancet. 2016 Apr 9;387(10027):1540-1550
references.pmid: 26712084
references.citation: J Immunol. 1999 Nov 15;163(10):5211-8
references.pmid: 10553041
references.citation: N Engl J Med. 2010 Aug 19;363(8):711-23
references.pmid: 20525992
references.citation: Cell Mol Immunol. 2010 Sep;7(5):389-95
references.pmid: 20514052
references.citation: P T. 2012 Sep;37(9):503-30
references.pmid: 23066344
references.citation: N Engl J Med. 2015 Jun 25;372(26):2509-20
references.pmid: 26028255
references.citation: Cancer Res. 2012 Oct 15;72(20):5209-18
references.pmid: 22915761
references.citation: Clin Cancer Res. 2014 Oct 1;20(19):5064-74
references.pmid: 24714771
references.citation: Immunol Rev. 2008 Aug;224:166-82
references.pmid: 18759926
references.citation: Lancet. 2014 Sep 20;384(9948):1109-17
references.pmid: 25034862
references.citation: Semin Oncol. 2015 Jun;42(3):363-77
references.pmid: 25965355
references.citation: Nat Rev Immunol. 2008 Jun;8(6):467-77
references.pmid: 18500231
references.citation: Cell. 2015 Apr 9;161(2):205-14
references.pmid: 25860605
references.citation: Nature. 2014 Nov 27;515(7528):563-7
references.pmid: 25428504
references.citation: Lancet Oncol. 2015 Aug;16(8):908-18
references.pmid: 26115796
references.citation: Arch Intern Med. 2003 Jul 28;163(14):1637-41
references.pmid: 12885677
references.citation: N Engl J Med. 2015 Oct 22;373(17):1627-39
references.pmid: 26412456
references.citation: J Clin Oncol. 2015 Jun 20;33(18):2013-20
references.pmid: 25800770
references.citation: Cancer Immunol Res. 2014 Sep;2(9):846-56
references.pmid: 24872026
references.citation: N Engl J Med. 2015 May 21;372(21):2006-17
references.pmid: 25891304
references.citation: Clin Cancer Res. 2015 Oct 1;21(19):4286-93
references.pmid: 25977344
references.citation: J Clin Oncol. 2015 May 1;33(13):1430-7
references.pmid: 25452452
references.citation: Nature. 2014 Nov 27;515(7528):558-62
references.pmid: 25428503
references.citation: N Engl J Med. 2015 Jul 9;373(2):123-35
references.pmid: 26028407
references.citation: N Engl J Med. 2015 Jun 25;372(26):2521-32
references.pmid: 25891173
references.citation: Nature. 2012 Sep 27;489(7417):519-25
references.pmid: 22960745